ORPH

6-K - Orphazyme A/S (0001764791) (Filer)

20-F - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

NT 20-F/A - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

NT 20-F - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

Orphazyme A/S in restructuring (ORPHA.CO) ("Orphazyme" or the "Company"), a late-stage biopharmaceutical company, has today received a notice from The Bank of New York Mellon, as depositary (the "Depositary"), that a notification has been sent to holders of American Depositary Shares ("ADSs") evidenced by American Depositary Receipts ("ADRs") representing deposited common shares of the Company, regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, the Depositary, and Owners and ADR Holders (the "Deposit Agreement"). Owners and beneficial owners of the above ADRs ("ADR Holders") have on April 5, 2022 been notified by the Depositary that the Depositary wil

6-K - Orphazyme A/S (0001764791) (Filer)

15-12B - Orphazyme A/S (0001764791) (Filer)

6-K - Orphazyme A/S (0001764791) (Filer)

-Reuters

6-K - Orphazyme A/S (0001764791) (Filer)

EFFECT - Orphazyme A/S (0001764791) (Filer)

Orphazyme A/S (NASDAQ:ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to consider the best possible path forward for arimoclomol," commented Orphazyme Chief Executive Officer Anders Vadsholt. The decision follows CHMP's negative trend vote on arimoclomol application following an Oral Explanation. Orphazyme is currently under an in-court restructuring and has reduced its workforce by approximately 50% to reduce costs.  As part of the pursuit of a regulatory pathway in the U.S., the Company co

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer Merck & Co., Inc. (NYSE:MRK) said the U.S. Food and Drug Administration has approved its cancer immunotherapy as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, as determined by a FDA-approved test. These patients should have had disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Merck shares were up 0.18% to $79.20 in premarket trading. Pfizer

6-K - Orphazyme A/S (0001764791) (Filer)